Close Menu
October 29, 2020
Sponsored by
Illumina

How to Train Your DRAGEN for Pathology Informatics

GenomeWebinar

Laboratory Director,
Xing Cancer Care

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

In this webinar, Lynn Fink of Xing Cancer Care will discuss how her ISO15189-accredited lab has used BSSH to support informatics data analysis as part its routine testing and will share details of why the lab chose this platform over other options.

In particular, Lynn will share how the lab uses the BSSH-hosted DRAGEN (Dynamic Read Analysis for Genomics) apps — Enrichment, Germline, and Somatic — to perform in-depth coverage analyses of a 1,000 cancer gene panel, germline alteration calling, and tumor-normal paired somatic alteration calling, respectively. These apps support about 95 percent of the lab’s analytical needs.

Sponsored by

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Sep
23
Sponsored by
Beckman Coulter

This webinar will discuss a streamlined library preparation method for next-generation sequencing (NGS) that improves quality control testing capability while reducing the total number of steps compared to conventional multiplexed library workflows.

Sep
24
Sponsored by
ArcherDX

NTRK fusions are oncogenic drivers in a variety of tumors.

Oct
06
Sponsored by
10x Genomics

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease characterized by irreversible scarring of the distal lung, leading to respiratory failure. 

Oct
14
Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.